Location: Manama, Bahrain | Date: June 18, 2024
YC Biotech CO., LTD. was honored to participate in a prestigious medical conference organized by the Economic Development Board (EDB Bahrain). Representing Taiwan’s biotechnology industry, YC Biotech showcased its groundbreaking advancements in stem cell exosome technology and cancer methylation detection to key officials and medical experts in the Kingdom of Bahrain. This event not only emphasized the international competitiveness of Taiwan’s medical technologies but also established a solid foundation for future collaboration in precision medicine and regenerative medicine.
Organized by EDB Bahrain, the conference is a cornerstone of the Kingdom’s efforts to elevate its biotechnology and healthcare sectors. It attracted prominent leaders and experts from across the Middle East, including HE Iain Lindsay OBE, Advisor to EDB Bahrain; Ahmed Sultan, Executive Director of International Affairs; and Aurelio Castilla, Head of International Affairs.
The Kingdom of Bahrain, a regional frontrunner in precision medicine and regenerative medicine, showed significant interest in YC Biotech’s technologies. At the conference, YC Biotech representatives presented comprehensive insights into the applications of stem cell exosome technology, which promotes tissue regeneration, reduces inflammation, and modulates immune responses. Additionally, they highlighted the role of cancer methylation detection technology in early screening and precise diagnosis, contributing to higher success rates in cancer treatment.
EDB Bahrain expressed strong enthusiasm for YC Biotech’s innovations and their potential applications. In-depth discussions were held on potential collaborative opportunities, including technology transfer and localized pilot projects. Bahrain aims to leverage these partnerships to enhance its local healthcare industry and solidify its leadership in the Middle East’s biotechnology and healthcare markets.
YC Biotech remains committed to deepening its collaboration with the Kingdom of Bahrain and other international partners. The company will continue to push the boundaries of precision and regenerative medicine, offering integrated biotech solutions and improving healthcare outcomes for patients worldwide.
